Despite survey data showing that safety concerns prompted many arthritis sufferers to switch from drugs to supplements last fall, some manufacturers of joint-care supplements said the COX-2 inhibitor recalls and warnings were insignificant to the category. “We’re seeing an increase in sales, but I don’t believe it has anything to do with the prescription drug issue,” said Harvey Kamil, president & chief financial officer of NBTY, which markets Osteo Bi-Flex and o
All access premium subscription
This content requires a subscription to Nutrition Business Journal.
As an NBJ subscriber, you receive 10 issues a year and access to the exclusive “NBJ subscriber only” content on newhope.com (excludes three-month subscriptions), which includes PowerPoint presentations, select data charts and archived articles. Subscribers also receive a 10 percent discount on data charts, comprehensive market research reports and webinars.
Email [email protected] for more information about subscribing.